NEW YORK – Recurrence scores from Genomic Health's Oncotype DX test might have a different meaning for men with breast cancer, suggesting a need for a lower cutoff score to predict mortality among male patients, a new study has found.
NEW YORK – Recurrence scores from Genomic Health's Oncotype DX test might have a different meaning for men with breast cancer, suggesting a need for a lower cutoff score to predict mortality among male patients, a new study has found.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.